about
Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)Role of antibiotics for treatment of inflammatory bowel diseaseProbiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseasesPostexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events.Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.Ciprofloxacin-Induced Thrombotic Thrombocytopenic Purpura: A Case of Successful Treatment and Review of the Literature.Usefulness of In Vivo and In Vitro Diagnostic Tests in the Diagnosis of Hypersensitivity Reactions to Quinolones and in the Evaluation of Cross-Reactivity: A Comprehensive Study Including the Latest Quinolone Gemifloxacin.Peripheral neuropathy associated with fluoroquinolones.Moxifloxacin safety: an analysis of 14 years of clinical data.Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent.Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection.Prulifloxacin: a new antibacterial fluoroquinolone.Torsades de pointes associated with fluoroquinolones.Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections.Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.Hepatic safety of antibiotics used in primary careMultiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.Nontuberculous mycobacterial pulmonary infection in patients with cystic fibrosis: diagnosis and treatment.Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Role of metabolism in drug-induced idiosyncratic hepatotoxicity.Immunologic evaluation of ofloxacin hypersensitivityBiphasic anaphylaxis to gemifloxacin.The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions.Ocular toxicity of fluoroquinolones.Clinical and histopathologic features of fluoroquinolone-induced liver injury.Severe QT interval prolongation associated with moxifloxacin: a case reportTumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposureCiprofloxacin-induced Hepatotoxicity in a Healthy Young AdultImmediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature.Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumoniaQuinolones: review of psychiatric and neurological adverse reactions.Antimicrobials for bacterial bioterrorism agents.Fluoroquinolone-induced liver injury: three new cases and a review of the literature.Antibiotic induced liver injury: what about children?Easy-Assessment of Levofloxacin and Minocycline in Relevant Biomimetic Media by HPLC-UV Analysis.Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patientA study on the toxicity of intravitreal levofloxacin in rabbits.Effect of Antibiotic Class on Stroke Outcome.
P2860
Q24236124-889A60F5-A203-47AE-93EF-CD9E6AF21BA3Q26774552-595AFE69-17CF-49CA-A913-C159A5F0EFF2Q26800020-45573DBA-DE57-44C6-A5EE-40ED9874EE8CQ30151571-3C9487E7-2579-43E7-8F58-4F1D42C88022Q33155516-E76753D5-08C4-429B-94BA-B1559A825D56Q33427695-5A639EC5-97B1-46D1-971E-979B700599B0Q33734355-127C62AA-6652-4C70-99F1-1C8324B34E93Q33956873-53E3785C-8F4F-4D20-9734-EBF718C632D6Q34310568-027996AA-AED3-4A35-BCA9-8FF047D3DF4BQ34372538-9070EB90-BD5D-4995-B1CB-A1945B4D4412Q34443701-5706C710-D2FB-4B07-8395-93ABE6E3647EQ34564526-9B6AC75A-9703-47EC-8961-603E7657F6CCQ34639737-A9B1F3F8-1C3C-48EE-8B91-577D4CB05CA9Q34789110-F1974161-1620-447E-9133-9FC228B6657CQ34941542-2E222853-1B79-469B-9575-D2322FC42EFCQ35037383-B07DC98F-6A25-4022-9C0B-4C90BE26CCBDQ35102747-211BF634-513D-409A-92B6-B5A2E19D3E9BQ35627888-4A5473AE-F4BA-4684-B7AF-567D8629437BQ35917230-CCB3F903-9755-427B-BB7D-E4C664CE599FQ35964560-197FC987-08B7-4541-BE3D-6E9D561EC4C1Q36179528-6F0547F3-2953-4CAA-A673-A46E5F8BA082Q36341635-245F615D-A269-407E-BD7A-4CA8984ACBC8Q36365197-C5067072-DAA1-4568-BF08-49E8D223983CQ36562483-570DB459-263C-4C4F-82EC-633EDBA59B16Q36662857-F124FD40-A04D-45E0-BDC5-3FE8B6F1E97AQ36924311-CEA8A12A-38FC-4476-851A-D4902808B7DAQ37031426-295F334C-B267-4562-8238-C7767B041CF9Q37052214-B79587E8-1FB8-4276-8304-39FD75A7AC08Q37201343-3661AA19-F9F3-40BB-8A9A-1D0AE750B195Q37693803-77A5366E-9CD4-4780-B3FC-A4A75C8F3DF3Q37710230-9F8B8BEF-D001-412D-B8D3-109547B4777EQ37719126-0F4825C8-9C19-40DD-AF1B-EC85F90C1815Q37876399-3104D5AA-1A88-44BA-8CF7-E1757E6766DAQ37894696-D662B32A-3709-460E-9AAB-18A5F2F842ABQ37975927-29E54382-979D-4166-A584-210197749146Q38144140-EDDB5A80-20CB-4083-A4F5-2027144778B3Q38819222-02366F11-F074-4816-A8BF-1B4F953B2E63Q39741473-5C8D071B-740E-43CA-9A60-6B89DD906C90Q40630867-C3518BD3-9BFE-4FFB-9CEB-D86B1D408329Q40773178-76B6B02D-E593-4F91-9243-9D5206E42BFC
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The safety profile of the fluoroquinolones.
@ast
The safety profile of the fluoroquinolones.
@en
The safety profile of the fluoroquinolones.
@nl
type
label
The safety profile of the fluoroquinolones.
@ast
The safety profile of the fluoroquinolones.
@en
The safety profile of the fluoroquinolones.
@nl
prefLabel
The safety profile of the fluoroquinolones.
@ast
The safety profile of the fluoroquinolones.
@en
The safety profile of the fluoroquinolones.
@nl
P1476
The safety profile of the fluoroquinolones.
@en
P2093
P304
798-817; discussion 797
P356
10.1016/S0149-2918(00)80053-3
P577
2000-07-01T00:00:00Z